We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVS Health (CVS) Stock Declines While Market Improves: Some Information for Investors
Read MoreHide Full Article
CVS Health (CVS - Free Report) closed at $91.13 in the latest trading session, marking a -1.51% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.6%. Elsewhere, the Dow gained 0.03%, while the tech-heavy Nasdaq added 1.18%.
The stock of drugstore chain and pharmacy benefits manager has risen by 5.33% in the past month, leading the Medical sector's gain of 2.23% and the S&P 500's loss of 0.79%.
Market participants will be closely following the financial results of CVS Health in its upcoming release. The company plans to announce its earnings on November 4, 2026. The company is forecasted to report an EPS of $1.62, showcasing a 1.25% upward movement from the corresponding quarter of the prior year. In the meantime, our current consensus estimate forecasts the revenue to be $105.04 billion, indicating a 2.11% growth compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $8.02 per share and revenue of $418.17 billion, which would represent changes of +18.81% and +4.01%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for CVS Health. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. As of now, CVS Health holds a Zacks Rank of #3 (Hold).
Investors should also note CVS Health's current valuation metrics, including its Forward P/E ratio of 11.53. This denotes a discount relative to the industry average Forward P/E of 17.44.
One should further note that CVS currently holds a PEG ratio of 0.86. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical Services stocks are, on average, holding a PEG ratio of 1.69 based on yesterday's closing prices.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 152, which puts it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
CVS Health (CVS) Stock Declines While Market Improves: Some Information for Investors
CVS Health (CVS - Free Report) closed at $91.13 in the latest trading session, marking a -1.51% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.6%. Elsewhere, the Dow gained 0.03%, while the tech-heavy Nasdaq added 1.18%.
The stock of drugstore chain and pharmacy benefits manager has risen by 5.33% in the past month, leading the Medical sector's gain of 2.23% and the S&P 500's loss of 0.79%.
Market participants will be closely following the financial results of CVS Health in its upcoming release. The company plans to announce its earnings on November 4, 2026. The company is forecasted to report an EPS of $1.62, showcasing a 1.25% upward movement from the corresponding quarter of the prior year. In the meantime, our current consensus estimate forecasts the revenue to be $105.04 billion, indicating a 2.11% growth compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $8.02 per share and revenue of $418.17 billion, which would represent changes of +18.81% and +4.01%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for CVS Health. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. As of now, CVS Health holds a Zacks Rank of #3 (Hold).
Investors should also note CVS Health's current valuation metrics, including its Forward P/E ratio of 11.53. This denotes a discount relative to the industry average Forward P/E of 17.44.
One should further note that CVS currently holds a PEG ratio of 0.86. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical Services stocks are, on average, holding a PEG ratio of 1.69 based on yesterday's closing prices.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 152, which puts it in the bottom 39% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.